CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2023 Earnings Call Transcript

Operator: Thank you. This was the last question and that concludes our questions from the audience. We will now turn the call back to Yehiel Tal, CollPlant’s Chief Executive Officer for any closing remarks. Yehiel?

Yehiel Tal: Thank you, Eran. Our vision is to be the leaders in regenerative medicine, helping people live longer and better through our innovative collagen technology. Consequently, our goal is to create better alternatives and options for the future, such as novel products for regenerative aesthetic medicine applications, an unlimited supply of spare parts for the human body, including life-saving organs, and drugs developed without the need for animal testing. In closing, I want to reiterate our upcoming goals for this year. For the remainder of 2024, we plan to focus on advancing the development of a paradigm-shifting regenerative dermal and soft tissue filler program with AbbVie, extend our large animal studies with commercial-sized breast implants to generate additional safety and efficacy data to support our future clinical studies and commercialization of this program.

And continue to form collaborations with industry leaders for utilizing our rhCollagen and bioink technologies and continue discussions related to our existing programs and products. Thank you, everyone, for your time this morning and for joining us for today’s conference call. I will leave you with this closing slide featuring our very important and valued CollPlant team members.

Operator: Thank you. That concludes today’s conference call and you may now all disconnect.